DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

11 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

28 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

21 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

22 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

31 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Executive Team and Board of Directors Changes

26 янв 2024 16:30:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

17 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

04 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

26 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

20 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

13 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

07 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

04 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

20 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

13 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

09 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience to Participate in Three November Conferences

06 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

02 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

01 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

16 окт 2023 08:00:01 Источник Nasdaq GlobeNewswire